WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H598044
CAS#: 142373-60-2 (HCl)
Description: Tirofiban HCl is a platelet glycoprotein-IIb/IIIa receptor antagonist.
Hodoodo Cat#: H598044
Name: Tirofiban HCl
CAS#: 142373-60-2 (HCl)
Chemical Formula: C22H37ClN2O5S
Exact Mass: 476.21
Molecular Weight: 477.050
Elemental Analysis: C, 55.39; H, 7.82; Cl, 7.43; N, 5.87; O, 16.77; S, 6.72
Related CAS #: 150915-40-5 (HCl hydrate) 144494-65-5 (free base)
Synonym: Tirofiban hydrochloride; Tirofiban HCl; MK 383; MK-383; MK383; Aggrastat; L 700462; L-700462; L700462;
IUPAC/Chemical Name: (S)-2-(butylsulfonamido)-3-(4-(4-(piperidin-4-yl)butoxy)phenyl)propanoic acid hydrochloride
InChi Key: KPKFFYOMPGOQRP-BOXHHOBZSA-N
InChi Code: InChI=1S/C22H36N2O5S.ClH/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18;/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26);1H/t21-;/m0./s1
SMILES Code: O=C(O)[C@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)NS(=O)(CCCC)=O.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 477.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M. Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration. J Clin Pharm Ther. 1999 Apr;24(2):125-32. PubMed PMID: 10380064.
2: Saucedo JF, Garza L, Wolford DC, Cook SL, Ramanathan KB, Matin Z, McGrew FA, Jacoski MV, Jennings LK; Tennessee-Arkansas-Mississippi (TAM) Clinical Research Consortium. Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study). Am J Cardiol. 2004 May 15;93(10):1279-82. PubMed PMID: 15135704.
3: Yates YJ, Farias CL, Kazmier FR, Puckett CL, Concannon MJ. The effect of tirofiban on microvascular thrombosis: crush model. Plast Reconstr Surg. 2005 Jul;116(1):205-8. PubMed PMID: 15988269.
4: El-Bagary RI, Elkady EF, Farid NA, Youssef NF. Validated spectrofluorimetric methods for the determination of apixaban and tirofiban hydrochloride in pharmaceutical formulations. Spectrochim Acta A Mol Biomol Spectrosc. 2017 Mar 5;174:326-330. doi: 10.1016/j.saa.2016.11.048. Epub 2016 Dec 3. Erratum in: Spectrochim Acta A Mol Biomol Spectrosc. 2017 Jun 15;181:23. PubMed PMID: 27984753.
5: Jennings LK, Jacoski MV, White MM. The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors. J Interv Cardiol. 2002 Feb;15(1):45-60. Review. PubMed PMID: 12053684.
6: Proimos G. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors. J Thromb Thrombolysis. 2001 Apr;11(2):99-110. Review. PubMed PMID: 11406724.
7: Dyke CM. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective. Am Heart J. 1999 Oct;138(4 Pt 2):307-16. Review. PubMed PMID: 10502236.